SNIPR Biome ApS (“SNIPR”) announced on August 7, 2025 the closure of its EUR 35 million Series B funding round, attracting investments from new backers such as the Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovation (SPRIN-D), alongside existing investors including Lundbeckfonden BioCapital, North-East Family Office, and Wellington Partners.

The proceeds from this funding will be utilized to develop a CRISPR-Cas therapy that targets airway infections caused by Pseudomonas aeruginosa in cystic fibrosis (CF) patients. It will also facilitate the advancement of a CRISPR-based microbial intervention aimed at eliminating antibiotic resistance genes in humans across various bacterial species and environments. Furthermore, the funds will support the clinical development of the company’s CRISPR-based product, SNIPR001, which is currently undergoing a phase 1b trial in patients with hematologic cancer.

“This financing marks a pivotal milestone for SNIPR BIOME as we advance the clinical development of SNIPR001 for the prevention of blood stream infections and continue to expand our infectious disease pipeline targeting pathogens of critical importance,” stated Christian Grøndahl, Chief Executive Officer and Co-Founder of SNIPR BIOME. He further emphasized, “This support shows the importance of addressing antimicrobial resistance and infectious disease and the unique position of SNIPR BIOME in the development landscape.”

SNIPR BIOME is at the forefront of utilizing CRISPR-Cas technology to achieve selective, precise, and ultra-rapid bacterial eradication while preserving the integrity of the patient’s microbial community. Additionally, the SNIPR technology is designed to produce therapeutics selectively within targeted regions of the gastrointestinal tract. By leveraging the natural bacterial CRISPR-based adaptive immune system in a programmable manner, SNIPR targets bacteria based on their specific genomes.

‍